000 01471 a2200385 4500
005 20250518081019.0
264 0 _c20200903
008 202009s 0 0 eng d
022 _a1526-632X
024 7 _a10.1212/WNL.0000000000008944
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMullin, Kathleen
245 0 0 _aPotential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
_h[electronic resource]
260 _bNeurology
_c05 2020
300 _ae2121-e2125 p.
_bdigital
500 _aPublication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAdult
650 0 4 _aAnalgesics
_xtherapeutic use
650 0 4 _aAntibodies, Monoclonal
_xpharmacology
650 0 4 _aAntibodies, Monoclonal, Humanized
_xpharmacology
650 0 4 _aCalcitonin Gene-Related Peptide
650 0 4 _aCalcitonin Gene-Related Peptide Receptor Antagonists
_xpharmacology
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aMigraine Disorders
_xdrug therapy
650 0 4 _aReceptors, Calcitonin Gene-Related Peptide
_xdrug effects
700 1 _aKudrow, David
700 1 _aCroop, Robert
700 1 _aLovegren, Meghan
700 1 _aConway, Charles M
700 1 _aCoric, Vladimir
700 1 _aLipton, Richard B
773 0 _tNeurology
_gvol. 94
_gno. 20
_gp. e2121-e2125
856 4 0 _uhttps://doi.org/10.1212/WNL.0000000000008944
_zAvailable from publisher's website
999 _c30513494
_d30513494